ANRS CO2 SEROCO/HEMOCO - Multicentric Cohort of HIV Positive Patients

Head :Meyer Laurence, U822

Last update : 01/01/2019 | Version : 2 | ID : 60080

General	
Identification	
Detailed name	Multicentric Cohort of HIV Positive Patients
Sign or acronym	ANRS CO2 SEROCO/HEMOCO
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	CNIL no. 87-108 (17/11/1987)
General Aspects	
Medical area	Infectious diseases
Health determinants	Geography Social and psychosocial factors
Keywords	AIDS stage, morbidity, mortality, health events
Scientific investigator(s)	
(Contact)	
	Meyer
(Contact)	Meyer Laurence
(Contact) Name of the director	
(Contact) Name of the director Surname	Laurence
(Contact) Name of the director Surname Address	Laurence 94276 LE KREMLIN BICÊTRE
(Contact) Name of the director Surname Address Phone	Laurence 94276 LE KREMLIN BICÊTRE +33 (0)1 45 21 23 34
(Contact) Name of the director Surname Address Phone Email	Laurence 94276 LE KREMLIN BICÊTRE +33 (0)1 45 21 23 34 laurence.meyer@inserm.fr
(Contact) Name of the director Surname Address Phone Email Unit	Laurence 94276 LE KREMLIN BICÊTRE +33 (0)1 45 21 23 34 laurence.meyer@inserm.fr U822

Details	Involved in cohort network: COHORTES AC7, HEPAVIH - international: COHERE, EUROPEAN COHORT OF INJECTION DRUG USERS (Mr. PRINS, NETHERLANDS), CASCADE Involved in a European project: Cascade, Cohere.
Funding	
Funding status	Public
Details	ANRS
Governance of the database	
Sponsor(s) or organisation(s) responsible	Agence Nationale de Recherches sur le Sida et les hépatites virales (ANRS)
Organisation status	Public
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Inclusion method: Prospective Inclusion cut-off date: 01/01/2001
Database objective	
Main objective	General objective: to investigate spontaneous HIV disease progression and the treatment response of haemophiliac (HEMOCO) or non-haemophiliac (SEROCO) subjects. The prognostic role of markers, in particular CD4, HIV-RNA and HIV-DNA.
Inclusion criteria	SEROCCO: Seropositive HIV-1 patients (ELISA test confirmed by Western blot) with known date of contamination or whose HIV status is less than a year old (period between first positive sample date and the date the patient is enrolled in survey) and who do not have AIDS at baseline; attending

physicians from centres participating in the survey; who are 18 years old or over and have given their informed consent. HEMOCO: HIV-seropositive haemophiliacs (ELISA test confirmed by Western blot); attending physicians from centres participating in the survey, who are 3 years old and over and have given their informed consent. Consent is signed by the parties with parental authority of dependent minors or by

the legal guardians of minors under tutelage.

ropulation type	
Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years)
Population covered	Sick population
Gender	Male Woman
Geography area	Regional
French regions covered by the database	Île-de-France Provence - Alpes - Côte d'Azur
Detail of the geography area	Paris regions and PACA (21 centres).
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	01/1988
Date of last collection (YYYY or MM/YYYY)	01/2009
Size of the database	
Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	- 1551 (SEROCO) - 197 (HEMOCO)
Data	
Database activity	Data collection completed
Type of data collected	Clinical data

Population type

	Declarative data Biological data
Clinical data (detail)	Direct physical measures Medical registration
Details of collected clinical data	Clinical examination at baseline and every 6-month follow-up. Information collected during clinical examination: clinical, virological, immunological data, initiation and interruption of several antiretroviral drugs.
Declarative data (detail)	Paper self-questionnaire Face to face interview
Details of collected declarative data	Information collected by self-administered questionnaire: sexual behaviour. Interview questionnaire at baseline and every 6-month follow- up. Information collected during interview: behavioural practices.
Biological data (detail)	Type of samples taken: blood.
Presence of a biobank	Yes
Contents of biobank	Serum Fluids (saliva, urine, amniotic fluid, ?)
Details of biobank content	Serum bank, lymph bank, cell bank.
Health parameters studied	Health event/morbidity Health event/mortality Health care consumption and services
Care consumption (detail)	Medicines consumption
Procedures	
Data collection method	Self-administered questionnaire: entry from a paper questionnaire; Interviews: entry from a paper questionnaire; Clinical examinations: handwritten Biological analysis: handwritten
Quality procedure(s) used	Consistency request after electronic data is recorded. Missing data is managed by returning to source record. Physician reminder for follow-up visits. Patients are informed about the use of their data.
Participant monitoring	Yes
Details on monitoring of participants	Every 6 months.

Links to administrative sources	Yes
Linked administrative sources (detail)	CépiDc, RNIPP, InVS
Promotion and access	
Promotion	
Link to the document	http://tinyurl.com/HAL-ANRS-CO2
Description	List of publications in HAL
Link to the document	http://tinyurl.com/Pubmed-ANRS-CO2
Description	List of publications in Pubmed
Access	
Terms of data access (charter for data provision, format of data, availability delay)	Data may be used by academic teams. Data may not be used by industrial teams.
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only